DNA PROBE ASSAY FOR THE PHILADELPHIA TRANSLOCATION

费城易位 DNA 探针检测

• 批准号: 3506420
• 负责人: JOHN STEPHENSON
• 金额: $ 25.45万
• 依托单位: OSI PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-06-15 至 1991-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3506420
• 关键词: bone marrow; chromosome translocation; chronic leukemia; chronic myelogenous leukemia; diagnosis design /evaluation; gel electrophoresis; human subject; human tissue; molecular oncology; natural gene amplification; neoplasm /cancer diagnosis; neoplasm /cancer genetics; nucleic acid hybridization; nucleic acid probes; nucleic acid sequence; protooncogene

The study is designed to develop novel assays for the differential diagnosis of human Chronic Myelogenous Leukemia (CML). The basic method involves the use molecular techniques to detect the Ph1 chromosomal translocation. Hybridization with a labeled DNA probe identifies novel junctions between the cellular abl proto-oncogene, from chromosome 9, and the phl gene from chromosome 22. In CML the junctions occur with small breakpoint cluster region (bcr), and can be detected readily in genomic DNA. Assays based on the detection of novel junctions in messenger RNA also will be developed. Clinical evaluation of the assays, in comparison with cytogenetic analysis, will be completed. The assays have commercial application as a clinical laboratory test for the diagnosis and monitoring of leukemia patients.

这项研究旨在开发新的检测方法， 人慢性粒细胞白血病（CML）的诊断。 的基本方法 涉及使用分子技术检测Ph1染色体 易位 与标记的DNA探针杂交鉴定新的 来自9号染色体的细胞abl原癌基因之间的连接， 22号染色体上的phl基因 在慢性粒细胞白血病中， 断裂点簇区域（bcr），并且可以在基因组中容易地检测到。 DNA. 基于信使RNA中新接头检测的测定 也将得到发展。 比较分析的临床评价 进行细胞遗传学分析。 该测定具有商业价值。 作为临床实验室检测用于诊断和监测 白血病患者。

项目成果

Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia.

慢性粒细胞白血病费城 (Ph1) 易位 DNA 探针测定的临床评估。

• 发表时间: 1988
• 期刊: Leukemia
• 影响因子: 11.4
• 作者: Blennerhassett,GT;Furth,ME;Anderson,A;Burns,JP;Chaganti,RS;Blick,M;Talpaz,M;Dev,VG;Chan,LC;Wiedemann,LM
• 通讯作者: Wiedemann,LM